{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-083011","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.746856+00:00","generated_at":"2026-06-08T22:11:30.732851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24","bullets":["Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.","Cash, cash equivalents & investments of $74.0M as of Sept 30, expected to fund ops into Q2 2025.","R&D expenses rose to $6.2M from $3.5M, driven by TARA-002 clinical trial activities.","First patient dosed in Phase 2 ADVANCED-2 (NMIBC) and Phase 2 STARBORN-1 (lymphatic malformations) trials.","Preliminary results from ADVANCED-1EXP expansion trial in NMIBC on track for 1H24."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-083011","json":"https://secwatch.observer/filing/0001213900-23-083011.json","markdown":"https://secwatch.observer/filing/0001213900-23-083011.md","text":"https://secwatch.observer/filing/0001213900-23-083011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/ea187484-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:11:30.732851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da8a7013122bead854a89a0106f7af0a58d5d062","claim":"Protara Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $9.9 million, EPS $0.87 per share.","evidence_excerpt":"For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $9.9 million"},{"label":"EPS","value":"$0.87 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}